Acrivon Therapeutics legal chief sells 513 shares

After the withholding-related sale, Mary Miller directly held 81,202 Acrivon Therapeutics shares.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller sold 513 shares of common stock on October 22, 2026, at a weighted average price of $1.84 per share. The broker sale automatically satisfied the mandatory tax withholding requirement upon vesting of restricted stock units. Mary Miller directly held 81,202 shares afterward. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 513 shares

Net Sell 1 txn

Insider Miller Mary

Role Chief Legal Officer

Sold 513 shs ($943.92)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	513	$1.84	$943.92

Holdings After Transaction: Common Stock — 81,202 shares (Direct)

Footnotes (2)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. F2. The price reported in Column 4 above reflects the weighted average price of 513 shares sold by a broker on October 22, 2026, to satisfy the payment of withholding tax liability of the reporting person.

Key Figures

Common shares sold: 513 shares Weighted average sale price: $1.84 per share Direct shares held after transaction: 81,202 shares

3 metrics

Common shares sold 513 shares Sale on October 22, 2026

Weighted average sale price $1.84 per share Broker sale on October 22, 2026

Direct shares held after transaction 81,202 shares Following the October 22, 2026 transaction

Key Terms

restricted stock units, weighted average price, withholding tax liability

3 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"reflects the weighted average price of 513 shares"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

withholding tax liability financial

"payment of withholding tax liability"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ACRV shares did Mary Miller sell?

Mary Miller, Acrivon Therapeutics’ Chief Legal Officer, sold 513 shares on October 22, 2026, at a weighted average price of $1.84 per share. The broker sale satisfied mandatory tax withholding upon restricted stock unit vesting, and she directly held 81,202 shares afterward. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 04:04 PM EDT Accepted by SEC EDGAR 10/26/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/22/2026		S(1)		513	D	$1.84(2)	81,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. The price reported in Column 4 above reflects the weighted average price of 513 shares sold by a broker on October 22, 2026, to satisfy the payment of withholding tax liability of the reporting person.

	/s/ Adam D. Levy, Attorney-in-Fact	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)